456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors.
Saved in:
| Title: | 456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors. |
|---|---|
| Authors: | Postel-Vinay, S.1 (AUTHOR), Italiano, A.2 (AUTHOR), Martin Romano, P.3 (AUTHOR), Cassier, P.A.4 (AUTHOR), Siu, L.L.5 (AUTHOR), Lossos, I.S.6 (AUTHOR), Hilton, J.F.7 (AUTHOR), Mckean, M.A.8 (AUTHOR), Strauss, J.9 (AUTHOR), Falchook, G.S.10 (AUTHOR), de Jonge, M.J.A.11 (AUTHOR), Opdam, F.L.12 (AUTHOR), Rasco, D.13 (AUTHOR), Vermaat, J.S.14 (AUTHOR), Crossman, T.15 (AUTHOR), Zajac, M.16 (AUTHOR), Hainline, A.17 (AUTHOR), Kremer, B.18 (AUTHOR), Barbash, O.19 (AUTHOR), Gounder, M.M.20 (AUTHOR) |
| Source: | Annals of Oncology. 2022 Supplement 7, Vol. 33, pS746-S747. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2022.07.585 |
